ArticleKidney international reports2026
Anti-CD20 Therapies and Antinephrin Autoantibodies in IgA Nephropathy With Minimal Change Disease.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In IgA nephropathy (IgAN) with minimal change disease (MCD) (MCD-IgAN), the efficacy of anti-CD20 monoclonal antibodies (mAbs) and the profile of antinephrin antibodies remain poorly understood. Methods: We evaluated the efficacy of anti-CD20 mAbs or combined short-course low-dose steroids (anti-CD20 mAbs group) compared with full-dose prolonged steroids (steroids group) and assessed the prevalence of antinephrin antibodies in a retrospective cohort of patients with MCD-IgAN. Results: Total remission rates of nephrotic syndrome were comparable between the anti-CD20 mAbs group and the steroids group in 45 adult patients with MCD-IgAN. Notably, the anti-CD20 mAbs group achieved a longer recurrence-free period after complete remission than the steroids group (median 30.4 vs. 17.1 months, Conclusion: Our findings indicate that anti-CD20 mAbs represent an effective and safe therapeutic option for adult patients with MCD-IgAN. Circulating antinephrin antibodies were detectable and associated with a higher relapse rate, suggesting its potential utility as a biomarker of both disease activity and therapeutic target in this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.